Today, Almay is announcing a new mineral powder that’s been approved by the FDA to treat dry eyes.
The company is currently in a phase two trial of its new treatment, and will begin to offer it to consumers in the next few weeks.
Almay claims that its new mineral treatment is more effective than existing treatments and has been used in studies in countries including the UK, the US, Brazil, Canada, India, Australia, Japan, Germany, and Italy.
It’s important to note that this treatment does not cure dry eyes, but it does treat the underlying condition.
Almas claims it can help reduce the appearance of fine lines and wrinkles, improve the skin’s elasticity, and help with hyperpigmentation, which can result from the accumulation of toxins in the skin.
It also helps to reduce the risk of premature aging.
Almas claims its new technology is available to consumers at an affordable price of $30.
This is not the first time Almas has used the term “salicylic acid” to describe its new product, as the company first used the word “salicylate” to refer to the same ingredient in its salicylic-acid-based salicyclic anhydrous acid, which was marketed in the late 1980s.
In recent years, Almas added salicylimide to its salicylates, and added other salicylamides, including the anti-inflammatory salicycilamide.
If you want to know more about the technology behind Almas’ new treatment and the company’s use of salicylates in other products, check out our full coverage of the world’s most successful salicyamides.
The new salicylc acid treatment has a pH of 6.5, which is not as acidic as the 5.5 that many salicycles have traditionally been marketed with.
The company also claims that it has reduced the risk for eczema and psoriasis by as much as 20% in the past year.
AlMas claims that the new treatment has no side effects and does not cause any allergic reactions, so it should be available to everyone by the end of the year.